Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply

JAMA Oncol. 2022 Nov 1;8(11):1702. doi: 10.1001/jamaoncol.2022.4531.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aminopyridines / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Benzimidazoles / adverse effects
  • Breast Neoplasms* / drug therapy
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Neoadjuvant Therapy*
  • Receptor, ErbB-2

Substances

  • abemaciclib
  • Aminopyridines
  • Benzimidazoles
  • Receptor, ErbB-2